MINI REVIEW article
Front. Oncol.
Sec. Radiation Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1640754
This article is part of the Research TopicAI-Based Prognosis Prediction and Dose Optimization Strategy in Radiotherapy for Malignant TumorsView all 7 articles
Hypoxia-inducible factor drives radiotherapy resistance and represents a therapeutic target in osteosarcoma
Provisionally accepted- 1Henan University of Chinese Medicine, Zhengzhou, Henan Province, China, Zhengzhou, China
- 2Department of Radiotherapy, Henan Cancer Hospital, Zhengzhou, Henan Province, China, Zhengzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Osteosarcoma, the most common primary malignant bone tumor, is characterized by aggressive behavior, early metastasis, and poor prognosis, particularly in patients with advanced disease. Despite multimodal treatment involving surgery and chemoradiotherapy, therapeutic resistance remains a major challenge, partly due to the hypoxic tumor microenvironment. Hypoxia-inducible factors (HIFs), particularly HIF-1α and HIF-2α, play pivotal roles in osteosarcoma progression by regulating stemness, metastasis, and resistance to chemotherapy and radiotherapy. Under hypoxia, HIFs activate key pathways (TGF-β, Wnt/β-catenin, Notch, and Hedgehog) to sustain osteosarcoma stem cells (OSCs), promote multidrug resistance (MDR) via efflux transporters (MRP1/P-GP), and confer radioresistance by enhancing DNA repair and metabolic adaptation. Emerging evidence suggests that HIF inhibitorssuch as EZN-2968, curcumin, and 2-methoxyestradiol-can disrupt these pathways, sensitizing tumors to conventional therapies. This review synthesizes current knowledge on HIF-driven mechanisms in osteosarcoma and highlights the therapeutic potential of targeting HIF signaling to overcome treatment resistance and improve clinical outcomes.
Keywords: Osteosarcoma, Hypoxia-inducible factors, radioresistance, multidrug resistance, hypoxiainducible factor (HIF) inhibitors, osteosarcoma therapy
Received: 04 Jun 2025; Accepted: 16 Jul 2025.
Copyright: © 2025 Fu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jinsong Liu, Department of Radiotherapy, Henan Cancer Hospital, Zhengzhou, Henan Province, China, Zhengzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.